Table 2 Follow-up data for each study group

 At follow-up^a

28 (0, 53)

20 (3, 50)

29 (0, 46)

 Participants with fatigue (MFIS total score ≥38)

2/10

2/10

2/10

 Change to baseline^a

−9.5 (−31, 5)

−13 (−28, 7)

−3 (−17, 4)

 At follow-up^b

5.2 (3.6, 6.7)

4.5 (3.7, 5.2)

5.5 (4.5, 6.6)

 Change to baseline^b

−0.9 (−1.3, −0.5)

−0.9 (−1.3, −0.5)

0.4 (−0.3, 1.1)

 Effect size^c

1.27 (0.26, 2.17)

1.27 (0.26, 2.17)

 Participants with clinically significant improvement (≥20 %)^d

3/10

3/10

0/10

30 % (7, 65 %)

30 % (7, 65 %)

0 % (0)

 At follow-up^b

521.1 (428.8, 613.5)

521.1 (454.1, 588.0)

475.3 (384.9, 565.8)

 Change to baseline^b

68.1 (51.4, 84.7)

92.9 (55.2, 130.5)

−9.4 (−35.6, 16.9)

 Effect size^c

1.91 (0.79, 2.88)

1.72 (0.64, 2.67)

 Participants with clinically significant improvement (≥20 %)^d

2/10

6/10

0/10

20 % (2, 56 %)

60 % (26, 88 %)

0 % (0)